


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**

**DATA FROM FOUR STUDIES OF “TQC3721 (PDE3/4 INHIBITOR)”, “TQC2731 (TSLP MONOCLONAL ANTIBODY)” AND “TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE POWDER FOR INHALATION)” PRESENTED AT ERS 2025**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the results from four studies of “TQC3721 (PDE3/4 inhibitor)”, “TQC2731 (TSLP monoclonal antibody)” and “TQC3403 (umeclidinium bromide and vilanterol trifenate powder for inhalation)” will be presented at the 2025 Annual Meeting of European Respiratory Society (ERS 2025) which will be held from 27 September to 1 October.

**TQC3721 (PDE3/4 inhibitor)**

TQC3721 is an inhaled PDE3/4 inhibitor with a new mechanism which has both bronchodilatory and anti-inflammatory effects, thus relieving the patients’ symptoms and suppressing inflammations. Currently, there is only one inhaled PDE3/4 inhibitor approved for marketing worldwide. In the Phase II clinical trial, TQC3721 demonstrated a satisfactory profile of dose-response relationship and safety. Based on the data from the study, TQC3721 has been granted the Breakthrough Therapy Designation by the Centre for Drug Evaluation (CDE) of the National Medical Products Administration of China and is currently undergoing the Phase III clinical trial domestically. In addition to the inhalation suspensions, the inhaled dry powder formulation of TQC3721 is set to commence the Phase II clinical trial in anticipation of further enhancement of the efficacy and patient compliance.

Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China(PACER- II): a phase 2, multicentre, randomized, double-blind, placebo-controlled trial

First Author: Luo Zhu, West China Hospital, Sichuan University

Corresponding Author: Li Weiman, West China Hospital, Sichuan University

## **TQC2731 (TSLP monoclonal antibody)**

TQC2731 is a humanized monoclonal antibody, which blocks its binding to receptors and inhibits downstream pathways by targeting TSLP, thereby reducing acute attacks of asthma. In addition to asthma, TSLP is closely associated with the incidence of various autoimmune diseases, chronic inflammatory diseases, and allergic diseases. Studies have also been undergone on TQC2731 for indications including chronic rhinosinusitis with nasal polyps (Phase III clinical trial), severe asthma (Phase III clinical trial), and COPD (Phase II clinical trial). Currently, there is only one TSLP monoclonal antibody approved for marketing worldwide, and TQC2731 is the fastest-progressing TSLP monoclonal antibody produced domestically.

Dose Optimization and Exposure-Response Analyses to Support the Dose Selection of TQC2731, a Novel Anti-TSLP Monoclonal Antibody, in Patients with Severe Asthma

First Author: Zhu Shixing, Chia Tai Tianqing Pharmaceutical Group

Corresponding Author: Yu Ding, Chia Tai Tianqing Pharmaceutical Group

Phase 1 study of TQC2731 targeting thymic stromal lymphopoietin in Chinese healthy adults and asthma patients

First Author: Tian Xin, The First Affiliated Hospital of Zhengzhou University

Corresponding Author: Yang Anqi, Chia Tai Tianqing Pharmaceutical Group

## **TQC3403 (umeclidinium bromide and vilanterol trifenate powder for inhalation)**

TQC3403 is an inhaled dry powder formulation combining umeclidinium bromide, the long-acting muscarinic antagonist (LAMA), with vilanterol, the long-acting  $\beta$  2-adrenergic agonist (LABA), thereby achieving long-acting bronchodilation through a dual mechanism of action. The original formulation was approved in China in 2018. Currently, there are no approved generic versions of this drug or its equivalents available in China. The Group has overcome challenges in multiple key core technologies and is the first party in China to complete equivalence studies on dry powder formulation as dual bronchodilators, which is expected to obtain approval for marketing in the first half of 2026, and become the first marketed generic drug of the umeclidinium bromide and vilanterol trifenate powder for inhalation.

Efficacy and Safety of TQC3403 in Patients with COPD: a Phase 3, Multicenter, Randomized, Open-label Clinical Equivalence Trial

First Author: Chen Dandan, Shenzhen People's Hospital

Corresponding Author: Chen Rongchang, Shenzhen People's Hospital

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 25 August 2025

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*